GlucoTrack, Inc. (GCTK)
NASDAQ: GCTK · Real-Time Price · USD
0.262
-0.002 (-0.76%)
Dec 27, 2024, 4:00 PM EST - Market closed
Company Description
GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States.
It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.
The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021.
GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
GlucoTrack, Inc.
Country | United States |
Founded | 2001 |
Industry | Medical Instruments & Supplies |
Sector | Healthcare |
Employees | 6 |
CEO | Paul Goode |
Contact Details
Address: 301 Route 17 North, Suite 800 Rutherford, New Jersey 07070 United States | |
Phone | 201 842 7715 |
Website | glucotrack.com |
Stock Details
Ticker Symbol | GCTK |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001506983 |
CUSIP Number | 45824Q507 |
ISIN Number | US45824Q5071 |
Employer ID | 98-0668934 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Paul V. Goode Ph.D. | Chief Executive Officer, President and Director |
Mark Tapsak Ph.D. | Vice President of Technology |
Drinda Benjamin | Vice President of Marketing |
James P. Thrower Ph.D. | Vice President of Engineering |
Avner Gal MBA, MSc.EE | Co-Founder, Chairman Emeritus, Consultant and Member of Scientific and Clinical Advisory Board |
David Malka BA | Co-Founder |
James S. Cardwell | Chief Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 17, 2024 | 424B5 | Filing |
Dec 17, 2024 | 8-K | Current Report |
Dec 6, 2024 | DEF 14A | Other definitive proxy statements |
Dec 3, 2024 | 8-K | Current Report |
Nov 22, 2024 | PRE 14A | Other preliminary proxy statements |
Nov 18, 2024 | 8-K | Current Report |
Nov 14, 2024 | 8-K | Current Report |
Nov 14, 2024 | 10-Q | Quarterly Report |
Nov 14, 2024 | 424B4 | Prospectus |
Nov 13, 2024 | 8-K | Current Report |